atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in the following upcoming investor conferences in November:
Presentation details can be found below:
- Berenberg US CEO Conference 2021
Format: 1×1 Meetings
Dates: Tuesday, November 9th, 2021 – Wednesday, November 10th, 2021
- Credit Suisse 30th Annual Healthcare Conference
Format: Fireside Chat
Date and Time: Thursday, November 11th, 2021, 9:40 a.m. ET
Webcast Link: https://kvgo.com/cs-2021-healthcare-conf/atai-life-sciences-nov
- 12th Annual Jefferies London Healthcare Conference
Format: Fireside Chat
Date and Time: Thursday, November 18th, 2021, 8:00 a.m. ET
Webcast Link: https://wsw.com/webcast/jeff201/atai/1818738
The presentations and archived webcasts will also be accessible in the Events section of atai’s website.
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.
atai’s business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders.
atai’s mission is to bridge the gap between what the mental healthcare system currently provides and what patients need. atai is headquartered in Berlin, with offices in New York and London. For more information, please visit www.atai.life.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors discussed under the caption “Risk Factors” in atai’s prospectus pursuant to Rule 424(b) filed with the U.S. Securities and Exchange Commission (“SEC”) on June 21, 2021, as such factors may be updated from time to time in atai’s other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.
Contact Information
Investor Contact:
Chad Messer
VP, Investor Relations, atai Life Sciences
Email: [email protected]
Media Contact:
Camilla Dormer
VP, Communications, atai Life Sciences
Email: [email protected]